The long QT syndrome (LQTS) is one of the first identified and most studied channelopathies where genetics can play a role in inheritance of abnormal prolongation of ventricular repolarization predisposing these given individuals to life threatening ventricular arrhythmias and sudden cardiac death. This QT prolongation can also be brought forth in an acquired manner (relating to use of certain medications, electrolyte disturbances or certain cardiac diseases). We explore the the current available pharmacotherapeutic options for the treatment of LQTS and emphasize their use as first line agents while mentioning other non-pharmacological interventions that we sometimes resort to. We delve into the molecular genetics, clinical features, genotype-phenotype correlations and genotype-specific approaches in treatment and mention some of the pharmacological treatment options that have promising features for use in the future .